Navigation Links
Enobia Pharma Receives FDA Orphan Drug Designation for Hypophosphatasia Product Candidate ENB-0040
Date:9/19/2008

with age. Clinical severity ranges from the severe perinatal or infantile form, with profound skeletal hypomineralization and respiratory compromise often causing death, to a more slowly progressive and debilitating osteomalacia in adults.

In the infantile form, infants may appear normal at birth but develop serious symptoms in the first six months of life. These can include failure to thrive, respiratory failure, fractures, and seizures. Radiographic findings include generalized hypomineralization and rickets. Mortality in these patients may be as high as 50%. In the childhood form, patients have varying degrees of hypomineralization, frank rickets, short stature, bone pain, muscle weakness, delayed motor milestones, early loss of deciduous teeth, and may experience frequent, poorly-healing fractures. In the adult form, the underlying osteomalacia causes bone pain due to overt or poorly-healing stress fractures that in some cases stops ambulation.

About ENB-0040

ENB-0040 is a fusion protein that includes the catalytic domain of human tissue non-specific alkaline phosphatase (TNSALP), an immunoglobulin Fc domain and a patented anionic peptide used to target the enzyme to bone. Preclinical studies of ENB-0040 in the "knockout" mouse model of severe hypophosphatasia were recently published in the Journal of Bone and Mineral Research [June 2008:23:777-787] and showed that subcutaneous administration of ENB-0040 significantly improved survival and prevented the skeletal and dental manifestations of the disease.

About Enobia Pharma Inc.

Enobia Pharma Inc., is a private, Montreal based company focused on the development of therapeutics to treat serious bone disorders for which there is no currently approved drug therapy. Enzyme Replacement Therapy for the treatment of hypophosphatasia is the Company's lead program. In 2007 Enobia completed a $40M Series B financing lead by OrbiMed Advisors and CTI Life Sciences.

Company Contact:
'/>"/>

SOURCE Enobia Pharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia
2. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
3. Memory Pharmaceuticals and Roche Expand R3487/MEM 3454 Development Program
4. Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
5. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
6. VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008
7. Unibioscreen and Drais Pharmaceuticals Partner to Develop and Commercialize UNBS 5162 for Treatment of Cancer
8. Vanda Pharmaceuticals Provides Update on Iloperidone
9. Cerimon Pharmaceuticals Announces Positive Results from a Phase II Clinical Study of Its Diclofenac Sodium Patch for Acute Pain
10. Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia
11. Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... PGI has announced an expansion of its ... at its San Luis Potosi, ... expansion is centered on solving the challenge of complicated ... personal care product manufacturers. The planned ... and packaging, will allow customers to take advantage of ...
(Date:3/31/2015)... , March 31, 2015  InMed Pharmaceuticals Inc. ... biopharmaceutical company that specializes in developing safer, more ... Paul C. Anderson , Ph.D., to its ... industry veteran who brings significant drug discovery and ... is a synthetic organic chemist by training with ...
(Date:3/31/2015)... March 31, 2015 ANI Pharmaceuticals, Inc. ("ANI") ... Propafenone Hydrochloride 150mg, 225mg and 300mg oral tablets, indicated ... overall US market for Propafenone Hydrochloride 150mg, 225mg and ... Health. Arthur S. Przybyl , President ... announce the launch of our fourth product from the ...
Breaking Medicine Technology:PGI Expands Manufacturing Capabilities At Mexico Plant 2InMed Pharmaceuticals Strengthens Scientific Advisory Board 2InMed Pharmaceuticals Strengthens Scientific Advisory Board 3InMed Pharmaceuticals Strengthens Scientific Advisory Board 4ANI Pharmaceuticals Announces the Launch of Propafenone Tablets 2ANI Pharmaceuticals Announces the Launch of Propafenone Tablets 3
... ofatumumab has activity in heavily pre-treated patients who have ... , PHILADELPHIA, Dec. 8 ... positive results from a pivotal trial pre-planned interim analysis ... lymphocytic leukemia (CLL). The results demonstrate the potential of ...
... Dec. 8 Alexion Pharmaceuticals,Inc. (Nasdaq: ... from AEGIS, an open-label,registration study examining Soliris(R) ... hemoglobinuria (PNH). The pre-specified,primary efficacy endpoint of ... 86,percent reduction (P<0.001). Key secondary endpoints including ...
Cached Medicine Technology:Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 2Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 3Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 4Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 5Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 6Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 7Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 8Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 9Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH 2Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH 3Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH 4Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH 5Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH 6Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH 7Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH 8
(Date:3/31/2015)... TX (PRWEB) March 31, 2015 One of the ... be a visit to Mount Kilauea on the big island. ... few places where you can see molten lava slowly oozing at ... on earth. , One place you would never expect ... the flat, arid terrain of Mission, Texas -- until now. , ...
(Date:3/31/2015)... Virginia (PRWEB) March 31, 2015 ... with Care Investment Trust LLC ("Care") a seniors ... Tiptree Financial Inc. Care announces today, their acquisition ... party seller for $54.48 million. Concurrent with the ... affiliates of Greenfield Senior Living ("Greenfield"). Pursuant to ...
(Date:3/31/2015)... The New Jersey Chapter of the ... two administrators from Windsor Healthcare Communities, a leading ... Jersey, to two key leadership roles at this ... administrator for Abingdon Care & Rehabilitation Center of ... administrator of Canterbury Care & Rehabilitation Center at ...
(Date:3/31/2015)... March 31, 2015 Tickets are now ... and Denver tradition since 1973. The 2015 Spring production, ... Showtime on Ice. On April 24 in partnership with ... and opening night tribute to the Pat Bowlen family, ... portion of the opening event proceeds will go to ...
(Date:3/31/2015)... March 31, 2015 Indiana Fiber ... Service Provider, announces that Joink, LLC selected IFN ... According to Cory Childs, IFN Enterprise Sales ... specifically targeted at Internet Service Providers, Telecom companies, ... service provides Joink with diverse protected transport from ...
Breaking Medicine News(10 mins):Health News:Rare Volcano Constructed inside Gold’s Gym in Mission, Texas 2Health News:Rare Volcano Constructed inside Gold’s Gym in Mission, Texas 3Health News:Greenfield Senior Living Inc. Enters Lease Transaction with Care Investment Trust LLC 2Health News:Greenfield Senior Living Inc. Enters Lease Transaction with Care Investment Trust LLC 3Health News:Abingdon Care & Rehabilitation Center’s Administrator Elected President of N.J. Chapter of the American College of Health Care Administrators 2Health News:Indiana Fiber Network, LLC was selected by Joink, LLC as Middle Mile Fiber Transport Provider 2Health News:Indiana Fiber Network, LLC was selected by Joink, LLC as Middle Mile Fiber Transport Provider 3
... ARBOR, Mich. -- As the Diagnostic and Statistical Manual of ... controversy about psychiatric diagnosis is reaching a fever pitch. ... and depression, among others, are eliciting great concerns. However, there ... "Almost no one likes the DSM, but no one ...
... (HealthDay News) -- Babies can understand many words sooner than ... Researchers from the University of Pennsylvania say 6- to 9-month ... foods and body parts through their daily exposure to language. ... comprehension is possible until a child is closer to 1 ...
... Fla. February 15, 2012 Sanford-Burnham Medical ... returned from Japan where they reviewed the progress ... their research partnership with Takeda Pharmaceutical Company Limited ... and evaluation of new therapeutic approaches to obesity. ...
... Researchers from the University of Exeter, Peninsula College of ... the South Western Ambulance Service NHS Foundation Trust (SWASFT) ... Trust (RD&E) to reduce the time it takes from ... vital clot-busting drug treatment. The researchers are from ...
... Laser light in combination with certain drugs known as ... used mostly to cure skin cancer. The reason that internal ... technology does not exist to check that the precise amount ... atomic physics at Lund University in Sweden looks like being ...
... problems developing motor skills, such as running, throwing a ball ... known whether those difficulties run in families or are linked ... in St. Louis points to autism as the culprit. ... "From our results, it looks like motor impairments ...
Cached Medicine News:Health News:Psychiatric diagnoses: Why no one is satisfied 2Health News:Babies May Be Smarter Than You Think 2Health News:Sanford-Burnham and Florida Hospital review obesity research progress with Takeda Pharmaceutical 2Health News:Sanford-Burnham and Florida Hospital review obesity research progress with Takeda Pharmaceutical 3Health News:Operational research seeks benefit for stroke victims 2Health News:Operational research seeks benefit for stroke victims 3Health News:New method makes it easier to treat prostate and pancreatic cancer 2Health News:Autism affects motor skills, study indicates 2Health News:Autism affects motor skills, study indicates 3
Bimod, acetabular cup "Xl" UHMWHDPE....
Metal on metal hip acetabular cups available for both cemented and cementless applications, the Biomet Merck metal on metal articulation hip system (M2aTM) combines proven materials with the latest i...
S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
Duraloc acetabular cup system....
Medicine Products: